Matjaz Barboric, PhD
Matjaz Barboric, PhDUniversity of Helsinki 2020 James A. Harting Pilot Study Award Targeting transcriptional kinases for novel ovarian cancer therapies Ovarian cancer is the deadliest gynecological cancer. Identifying druggable Achilles’ heels of ovarian cancer can lead to new treatments. In order to do this, Dr. Barboric will target critical enzymes called cyclin-dependent kinases (tCDKs) which […]
Keith Knutson, PhD
Keith Knutson, PhDMayo Clinic Jacksonville2020 Cookie Laughlin Pilot Study Award Combination Th17-inducing vaccination and immune checkpoint blockade for ovarian cancer treatment Several types of immunotherapies that use the person’s own immune system to attack foreign “cancer” cells while leaving normal cells alone are being tested in ovarian cancer. Using immunotherapy to activate an immune pathway […]
Ilana Chefetz, PhD
Ilana Chefetz, PhDUniversity of Minnesota – Twin Cities2020 Lynda’s Fund Pilot Study Award AMPK-alpha-like proteins in a high grade serous ovarian cancer Although epithelial ovarian cancer responds well to initial treatment, the cancer recurs in a significant number of women. Once ovarian cancer recurs it is generally lethal, with fewer than 10% of patients surviving […]
Joe Delaney, PhD
Joe Delaney, PhDMedical University of South Carolina2020 Pilot Study Award Slowing ovarian cancer evolution by LINE-1 inhibition High grade serous ovarian cancer is unique from other cancer types in that it has high levels of a type of DNA called LINE-1 elements. LINE-1 elements are known as selfish DNA because they can make copies of […]
Hua Yu, PhD
Hua E Yu, PhDBeckman Research Institute of the City of Hope2020 Karla Mooers Pilot Study Award Targeting dePARylation activates anti-ovarian cancer immune responses The FDA has approved several types of PARP inhibitors for treating ovarian cancer. These drugs are especially effective at killing tumor cells that cannot repair damage that occurs to their DNA. One […]
Matthew Wakefield, PhD
Matthew Wakefield, PhDThe Walter & Eliza Hall Institute of Medical Research2020 Rosser Family Pilot Study Award Identifying all mutations in the PARP1 catalytic domain that impact PARP inhibitor action PARP inhibitors are a class of drugs that are becoming a major part of treatment for high grade ovarian cancer. These drugs kill cancer cells by […]
Rosemary Foster, PhD
Rosemary Foster, PhDMassachusetts General Hospital Identification and Characterization of the Ovarian Cancer Stem Cell Cancer stem cells have recently been identified in some solid tumors and are thought to drive tumor formation. Most tumors likely contain rare subpopulations of stem-like cells that would serve as critical targets of more clinically effective therapies. Our research experiments […]
Melissa Fishel, PhD
Melissa Fishel, PhDIndiana University School of Medicine Enhancement of ovarian cancer to chemotherapeutics agents, cisplatin and TMZ, using small molecules, BG and MX With the exception of a small percentage of patients presenting with stage IA/IB ovarian cancer, surgery along is inadequate treatment. However, virtually all patients who die from ovarian cancer have intrinsic or […]
Mary Zhang, PhD
Mary Zhang, PhDUniversity of South Florida Role of HDAC6 and its novel substrate cortactin in ovarian cancer cell motility HDACs are a group of enzymes that regulate cell growth and migration, and hence are likely involved with the metastases of ovarian cancer. This study will examine the role between these enzymes and the molecular events […]
Jason Wilken, PhD, BS
Jason Wilken, PhD, BSYale University Overcoming Primary Herceptin Resistance in Ovarian Cancer Herceptin, a therapeutic antibody that targets ErbB2 and has a well-tolerated safety profile has proven exceptionally useful as a treatment for ErbB2+ breast cancer patients. Surprisingly, Herceptin has proven to be ineffective as a treatment option for ovarian cancer. Dr. Wilken, with the […]